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Background
T cells recognize cancer cells via human leukocyte antigen
(HLA)/peptide complexes, and class I HLA restricted
tumor infiltrating T cells correspond to favorable prog-
noses in several cancers, including ovarian cancer. Cancer-
specific HLA/peptide complexes therefore represent
tumor cell surface biomarkers, and the accurate identifica-
tion of HLA/peptide targets is a prerequisite for the devel-
opment of T cell therapies. Potential class I HLA
presented peptide fragments of human epidermal growth
factor receptor 2 (HER-2) have been identified using both
predictive algorithms and immunologic testing of HER-2
candidate peptides, including the controversial HER-2
peptide known as E75. Here, HLA were harvested directly
from ovarian cancer cells and their peptide cargo assessed
in order to determine which HER-2 peptides, including
E75, represent true HLA tumor ligands.
Methods and results
A secreted form of HLA-A*02:01 was stably transfected
into the immortalized normal ovarian epithelial cell line
FHIOSE-118 as well as into the SKOV-3 ovarian cancer
cell line which overexpresses HER-2. HLA class I was
harvested from both cell lines, the bound peptides com-
pared by mass spectroscopy, and two HER-2-derived
peptides were found unique to SKOV-3. One of these
two peptides has been reported to bind HLA-A*02:01
and to be immunogenic, while the second HER-2 pep-
tide represents a previously uncharacterized ligand. This
novel HER-2 ligand was tested by competitive binding
assay and found to have a high HLA-A*02:01 binding
affinity. Interestingly, the widely accepted HER-2 peptide
E75 was not present in the SKOV-3 peptide pool. To
determine if another peptide ligand might be immunolo-
gically cross-reactive with E75, we tested an antibody
that recognizes HLA-A*02:01/E75 for cross reactivity
with other HLA-A*02:01/peptide complexes in the
SKOV-3 line. Several HLA presented peptides represent
potential E75 analogs.
Conclusion
Class I HLA gathered from tumor lines provide for the
direct identification of cancer-specific T cell biomarkers.
Here, HLA class I gathered from ovarian cancer lines
confirms that both expected and novel HER-2 peptides
are available for T cell recognition, although the HER-2
peptides available for T cell targeting are not necessarily
those predicted by indirect methods. In regards to the
HLA-A*02:01/E75 ligand complex, our data coincide
with published data showing that neither the standard
nor the immunoproteasome are able to produce the E75
peptide. Gathering HLA from cancerous cells may pro-
vide more accurate knowledge of cancer epitopes, data
paramount to their application either as prognostic bio-
markers or in therapeutics such as peptide vaccination,
antibody therapy, or adoptive cell transfer.
Authors’ details
1University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
2Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P62
Cite this article as: Patterson et al.: Direct analysis of HLA/HER-2 peptide
epitopes. Journal for ImmunoTherapy of Cancer 2013 1(Suppl 1):P62.
1University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Full list of author information is available at the end of the article
Patterson et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P62
http://www.immunotherapyofcancer.org/content/1/S1/P62
© 2013 Patterson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
